InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
75%
T+90 mean return
+2.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by TETRAULT LYNN A., Director. Director active across 3 companies, notably Neogenomics INC. Cumulatively, 17 filings have been recorded. Split: 1 buy · 1 sell. Total volume traded: €141k. History available since 2 June 2021. The latest transaction was filed on 9 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations17 total
3,553 sharesCommon StockSEC:0001645512-26-000003:0
7,000 shares@ US$8.139225.3% of flowCommon StockSEC:0001077183-25-000100:0
Canonical exit: 7 Aug 2025 (T+90)
3,199 shares@ US$18.9933.1% of flowCommon StockSEC:0001104659-24-098944:0
4,300 shares@ US$18.9944.0% of flowCommon StockSEC:0001104659-24-094012:0
10,000 shares@ US$4.1522.8% of flowCommon StockSEC:0001104659-24-089634:0
11,336 shares0Common StockSEC:0001077183-24-000135:0
3,000 sharesCommon StockSEC:0001104659-24-074768:0
6,112 shares@ US$15.965144.8% of flowCommon StockSEC:0001077183-24-000034:0
1,507 shares@ US$11.608.1% of flowCommon StockSEC:0001077183-23-000064:0
15,556 shares0Common StockSEC:0001077183-22-000107:0
3,334 shares@ US$7.270.0022% mcap52.7% of flowCommon StockSEC:0001077183-22-000087:0
838 shares0Common StockSEC:0001077183-21-000227:0
838 shares0Common StockSEC:0001077183-21-000227
1,389 shares@ US$9.115.2% of flowCommon StockSEC:0001077183-21-000168
1,389 shares@ US$9.110.0010% mcap23.7% of flowCommon StockSEC:0001077183-21-000168:0
3,081 shares0Common StockSEC:0001077183-21-000158:0
3,081 shares0Common StockSEC:0001077183-21-000158
17 of 17 declarations
About TETRAULT LYNN A.
Lynn A. Tetrault is a Director at Neogenomics Inc. In this role, she contributes to corporate governance and the company's strategy. Her experience in the biotechnology sector allows her to provide valuable insights to strategic discussions within the board.
